Clinical Trial

Biomarkerscreening in Cervical Cancer and Its Preinvasive Lesions

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The following trial is a multicenter and prospective research trial of the colposcopy unit of luebeck university and the national research center in Borstel, Germany. The study is to identify and evaluate new biomarkers in human papilloma virus (HPV) associated malignancies and its preinvasive lesions of the cervix uteri. Fresh tissue samples being removed during conizations and/or hysterectomies are to be fixed in HOPE's solution and analyzed according to their transcriptomes and methylosome. The hereby found candidates are to be validated using immunohistochemistry and RT \[real-time\] -PCR \[polymerase chain reaction\]. The project is meant to be followed by continuous studies developing a new test describing the malignant potential of HPV associated genital lesions.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2014-09-10; most recent amendment 2022-05-27.
Status change: Recruiting → Active, Not Recruiting 2022-05-27
Trial Details
NCT Number NCT02238990
Lead Sponsor University of Luebeck
Conditions Evaluation of New Tissue Biomarkers for Cervical Cancer
Enrollment 100 participants
Start Date 2014-09
Primary Completion 2030-12-01 (estimated)
Study Completion 2030-12-01 (estimated)
Updated on ClinicalTrials.gov 2022-05-31